Rizzi Liara, Maria Portal Marcelle, Batista Carlos Eduardo Alves, Missiaggia Luciane, Roriz-Cruz Matheus
Division of Geriatric Neurology, Service of Neurology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos Street 2.350, 90035-903 Porto Alegre, RS, Brazil.
Brain Res. 2018 Jan 1;1678:27-31. doi: 10.1016/j.brainres.2017.10.008. Epub 2017 Oct 7.
Individuals with amnestic mild cognitive impairment (aMCI) are at a high risk to develop Alzheimer's disease (AD). We compared CSF levels of biomarkers of amyloidosis (Aβ) and neurodegeneration (p-Tau) in individuals with aMCI and with subjective cognitive impairment (SCI) in order to ascertain diagnostic accuracy and predict the odds ratio associated with aMCI.
We collected CSF of individuals clinically diagnosed with aMCI (33) and SCI (12) of a memory clinic of Southern Brazil. Levels of Aβ and p-Tau were measured by immunoenzymatic assay. Participants also underwent neuropsychological testing including the verbal memory test subscore of the Consortium to Establish a Registry for Alzheimer's Disease (VM-CERAD).
CSF concentration of Aβ was significantly lower (p: .007) and p-Tau/Aβ ratio higher (p: .014) in aMCI individuals than in SCI. However, isolate p-Tau levels were not associated with aMCI (p: .166). There was a statistically significant association between Aβ and p-Tau (R: 0.177; β: -4.43; p: .017). ROC AUC of CSF Aβ was 0.768 and of the p-Tau/Aβ ratio equals 0.742. Individuals with Aβ < 823 pg/mL levels were 6.0 times more likely to be diagnosed with aMCI (p: .019), with a 68.9% accuracy. Those with p-Tau/Aβ ratio > 0.071 were at 4.6 increased odds to have aMCI (p: .043), with a 64.5% accuracy. VM-CERAD was significantly lower in aMCI than among SCI (p: .041).
CSF Aβ, but not p-Tau level was significantly associated with aMCI.
遗忘型轻度认知障碍（aMCI）个体患阿尔茨海默病（AD）的风险很高。我们比较了aMCI个体与主观认知障碍（SCI）个体脑脊液中淀粉样变性（Aβ）和神经变性（p-Tau）生物标志物的水平，以确定诊断准确性并预测与aMCI相关的比值比。
我们收集了巴西南部一家记忆诊所临床诊断为aMCI（33例）和SCI（12例）个体的脑脊液。通过免疫酶测定法测量Aβ和p-Tau的水平。参与者还接受了神经心理学测试，包括阿尔茨海默病注册协会（VM-CERAD）言语记忆测试子分数。
aMCI个体脑脊液中Aβ浓度显著低于SCI个体（p：0.007），p-Tau/Aβ比值高于SCI个体（p：0.014）。然而，单独的p-Tau水平与aMCI无关（p：0.166）。Aβ与p-Tau之间存在统计学显著关联（R：0.177；β：-4.43；p：0.017）。脑脊液Aβ的ROC曲线下面积（AUC）为0.768，p-Tau/Aβ比值的AUC为0.742。Aβ水平<823 pg/mL的个体被诊断为aMCI的可能性高6.0倍（p：0.019），准确率为68.9%。p-Tau/Aβ比值>0.071的个体患aMCI的几率增加4.6倍（p：0.043），准确率为64.5%。VM-CERAD在aMCI个体中显著低于SCI个体（p：0.041）。
脑脊液Aβ水平而非p-Tau水平与aMCI显著相关。
